(Source: Enanta Pharmaceuticals Inc) Data from AbbVie’s SURVEYOR-I and SURVEYOR-II studies demonstrate high sustained virologic response rates at 12 weeks post-treatment (SVR 12 ) in non-cirrhotic patients with genotype 1 (GT1), genotype 2 (GT2) and genotype 3 (GT3) chronic hepatitis C virus (HCV) infection Late-breaking data demonstrate 97 percent SVR 12 in GT1 non-cirrhotic HCV patients after 8 weeks of treatment with ABT-493 and ABT-530 First patient enrolled in Phase 3 trials WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 16, 2015-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
↧